Publication:
Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023

Simple item page
dc.contributor.authorAntunes, Liliana
dc.contributor.authorMazagatos, Clara
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorGomez, Verónica
dc.contributor.authorBorg, Maria-Louise
dc.contributor.authorPetrović, Goranka
dc.contributor.authorDuffy, Róisín
dc.contributor.authorDufrasne, François E
dc.contributor.authorDürrwald, Ralf
dc.contributor.authorLazar, Mihaela
dc.contributor.authorJancoriene, Ligita
dc.contributor.authorOroszi, Beatrix
dc.contributor.authorHusa, Petr
dc.contributor.authorHoward, Jennifer
dc.contributor.authorMelo, Aryse
dc.contributor.authorPozo Sanchez, Francisco
dc.contributor.authorPérez-Gimeno, Gloria
dc.contributor.authorCastilla, Jesús
dc.contributor.authorMachado, Ausenda
dc.contributor.authorDžiugytė, Aušra
dc.contributor.authorKarabuva, Svjetlana
dc.contributor.authorFitzgerald, Margaret
dc.contributor.authorFierens, Sébastien
dc.contributor.authorTolksdorf, Kristin
dc.contributor.authorPopovici, Silvia-Odette
dc.contributor.authorMickiene, Aukse
dc.contributor.authorTúri, Gergő
dc.contributor.authorSoučková, Lenka
dc.contributor.authorNicolay, Nathalie
dc.contributor.authorRose, Angela Mc
dc.contributor.authorEuropean Hospital Vaccine Effectiveness Group
dc.contributor.funderUnión Europea. European Centre for Disease Prevention and Control (ECDC)
dc.date.accessioned2024-03-18T16:53:51Z
dc.date.available2024-03-18T16:53:51Z
dc.date.issued2024-01
dc.description.abstractWe conducted a multicentre hospital-based test-negative case-control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14-89 days post-vaccination, 15% (95% CI: -12 to 35) at 90-179 days, and lower to no effect thereafter.es_ES
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipThe Vaccine Effectiveness, Burden and Impact Studies studies (VEBIS) is a project of the European Centre for Disease Prevention and Control (ECDC) run under the framework contract No. ECDC/2021/016.es_ES
dc.format.number3es_ES
dc.format.page2300708es_ES
dc.format.volume29es_ES
dc.identifier.citationEuro Surveill. 2024 Jan;29(3):2300708.es_ES
dc.identifier.doi10.2807/1560-7917.ES.2024.29.3.2300708es_ES
dc.identifier.e-issn1560-7917es_ES
dc.identifier.journalEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletines_ES
dc.identifier.pubmedID38240061es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18998
dc.language.isoenges_ES
dc.publisherEuropean Centre for Disease Prevention and Control (ECDC)
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/ECDC/2021/016es_ES
dc.relation.publisherversionhttps://doi.org/10.2807/1560-7917.ES.2024.29.3.2300708es_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCOVID-19es_ES
dc.subjectCOVID-19 bivalent vaccineses_ES
dc.subjectEuropees_ES
dc.subjectHospitalisationes_ES
dc.subjectSARIes_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectVaccine effectivenesses_ES
dc.subjectXBBes_ES
dc.subject.meshCOVID-19 Vaccineses_ES
dc.subject.meshCOVID-19es_ES
dc.subject.meshHumanses_ES
dc.subject.meshCase-Control Studieses_ES
dc.subject.meshSARS-CoV-2es_ES
dc.subject.meshHospitalizationes_ES
dc.subject.meshEuropees_ES
dc.subject.meshRNA, Messengeres_ES
dc.titleEffectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023es_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicatione177bf8c-3734-480b-a2ae-4ae67491776c
relation.isAuthorOfPublication5611ffc3-de88-4908-b20a-9a15a58c060a
relation.isAuthorOfPublicationcd6d5fea-c769-479f-bdfa-1f76888459a3
relation.isAuthorOfPublication7ac13a7f-3d30-4846-8b51-b7505c7df45c
relation.isAuthorOfPublication.latestForDiscoverye177bf8c-3734-480b-a2ae-4ae67491776c
relation.isFunderOfPublication78e868cc-0192-448d-bcb1-98d618a7cee4
relation.isFunderOfPublication.latestForDiscovery78e868cc-0192-448d-bcb1-98d618a7cee4
relation.isPublisherOfPublication844b1441-479c-4219-87e5-efc493160a02
relation.isPublisherOfPublication.latestForDiscovery844b1441-479c-4219-87e5-efc493160a02

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
EffectivenessAdaptedBivalent_mRNA_2024.pdf
Size:
566.99 KB
Format:
Adobe Portable Document Format
Description:
Articulo
Download
Thumbnail Image
Name:
Supplementary_EffectivenessAdaptedBivalent_mRNA_2024.pdf
Size:
300.55 KB
Format:
Adobe Portable Document Format
Description:
supplementary material
Download

Collections

Centro Nacional de Epidemiología (CNE)
Centro Nacional de Microbiología (CNM)
IdiSNA - Instituto de Investigación Sanitaria de Navarra (Navarra)